SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed13d 15h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Watch for continued U.S. launch trajectory in acquired HO, initiation of pivotal Phase 3 trials for bivamelagon by year-end 2026, and European country-level launches beginning in 2027. The $750M loan facility provides significant financial flexibility for pipeline advancement.

DirectionBullish
Confidencehigh
Horizonweeks

IMCIVREE

▲ Bullish Named in this press release
Impact
Not rated
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, next catalyst and thesis.

Subscribe for Full Access

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$86.44
T+0 close · Nov 3, 2026 · via day close
Latest settled
+31.83%
T+5 · $113.95 · next T+20 in 15d
Vs SPY
+32.41%
α at T+5
Latest observation
+33.83%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $86.44entry
  2. T+1 · 13d ago +28.04%α +26.39% · $110.68
  3. T+5 · 7d ago +31.83%α +32.41% · $113.95
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals reported Q3 2026 IMCIVREE revenue of $92.1M, a 29% sequential increase and 80% YoY growth, beating the $84.6M consensus. Net loss per share of $(0.61) was narrower than the consensus estimate of $(0.74). The company also secured a $750M term loan facility and amended its bivamelagon license with LG Chem, reducing the royalty to 1% in exchange for $350M in fixed payments.

Key Financial Metrics

EPS
−$0.61
est −$0.74 · +17.6%
Revenue
$92.1M
est $84.6M · +8.9% · +79.6% YoY
Rating
beat

Key Facts

  • Q3 2026 IMCIVREE net product revenue of $92.1M, up 29% sequentially and 80% YoY from $51.3M
  • Revenue beat consensus of $84.6M by 8.9%
  • GAAP net loss per share of $(0.61) vs consensus estimate of $(0.74)
  • Over 700 patient start forms for IMCIVREE in acquired HO from more than 500 prescribers as of Sep 30, 2026
  • Entered into a five-year term loan facility for up to $750M, with $250M initial draw
  • Amended LG Chem bivamelagon license: $350M fixed payments over four years in exchange for reducing royalty to 1%
  • Cash, cash equivalents and short-term investments of $320.9M as of Sep 30, 2026 (excluding the $250M loan draw and $70M LG Chem payment)
  • Company expects cash to fund operations for at least 24 months
  • Non-GAAP operating expense guidance for FY2026: $360M-$380M

Financial Impact

Revenue beat of $7.5M (8.9%) vs consensus; net loss narrowed by $0.13/share vs consensus; $250M initial draw on $750M loan facility adds liquidity

revenuenet loss per sharecash positionoperating expenses

Risk Factors

  • Dependence on continued commercial success of IMCIVREE in acquired HO, a recently approved indication
  • $350M fixed payment obligation to LG Chem over four years creates significant cash outflow
  • R&D and SG&A expenses are growing rapidly (R&D +14% YoY, SG&A +27% YoY), pressuring path to profitability
  • Clinical and regulatory risks for bivamelagon and RM-718 pipeline candidates

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3394041

Track record

26 reports on RYTM

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Viewing Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026